# Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

> **NCT06503263** · PHASE2 · RECRUITING · sponsor: **Navy General Hospital, Beijing** · enrollment: 240 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Zanubrutinib plus Lenalidomide as Maintenance Therapy

## Key facts

- **NCT ID:** NCT06503263
- **Lead sponsor:** Navy General Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-30
- **Primary completion:** 2030-07-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06503263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06503263, "Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06503263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*